Literature DB >> 36102198

Impaired Dynamic Sarcoplasmic Reticulum Ca Buffering in Autosomal Dominant CPVT2.

Matthew J Wleklinski1, Dmytro O Kryshtal1, Kyungsoo Kim1, Shan S Parikh1, Daniel J Blackwell1, Isabelle Marty2, V Ramesh Iyer3, Bjӧrn C Knollmann1.   

Abstract

BACKGROUND: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal cardiac arrhythmia syndrome triggered by catecholamines released during exercise, stress, or sudden emotion. Variants in the calsequestrin-2 gene (CASQ2), encoding the major calcium (Ca) binding protein in the sarcoplasmic reticulum (SR), are the second most common cause of CPVT. Recently, several CASQ2 gene variants, such as CASQ2-K180R, have been linked to an autosomal dominant form of Casq2-linked CPVT (CPVT2), but the underlying mechanism is not known.
METHODS: A K180R mouse model was generated using CRIPSR/Cas9. Heterozygous and homozygous K180R mice were studied using telemetry ECG recordings in vivo. Ventricular cardiomyocytes were isolated and studied using fluorescent Ca indicators and patch clamp. Expression levels and localization of SR Ca-handling proteins were evaluated using Western blotting and immunostaining. Intra-SR Ca kinetics were quantified using low-affinity Ca indicators.
RESULTS: K180R mice exhibit an autosomal dominant CPVT phenotype following exercise or catecholamine stress. Upon catecholamine stress, K180R ventricular cardiomyocytes exhibit increased spontaneous SR Ca release events, triggering delayed afterdepolarizations and spontaneous beats. K180R had no effect on levels of Casq2, Casq2 polymers, or other SR Ca-handling proteins. Intra-SR Ca measurements revealed that K180R impaired dynamic intra-SR Ca buffering, resulting in a more rapid rise of free Ca in the SR during diastole. Steady-state SR Ca buffering and total SR Ca content were not changed. Consistent with the reduced dynamic intra-SR buffering, K180R causes reduced SR Ca release refractoriness.
CONCLUSIONS: CASQ2-K180R causes CPVT2 via a heretofore unknown mechanism that differs from CASQ2 variants associated with autosomal recessive CPVT2. Unlike autosomal recessive CASQ2 variants, K180R impairs the dynamic buffering of Ca within the SR without affecting total SR Ca content or Casq2 protein levels. Our data provide insight into the molecular mechanism underlying autosomal dominant CPVT2.

Entities:  

Keywords:  calcium; calsequestrin; catecholamine; sarcoplasmic reticulum; tachycardia

Mesh:

Substances:

Year:  2022        PMID: 36102198      PMCID: PMC9529867          DOI: 10.1161/CIRCRESAHA.121.320661

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   23.213


  44 in total

1.  F110I and R278C troponin T mutations that cause familial hypertrophic cardiomyopathy affect muscle contraction in transgenic mice and reconstituted human cardiac fibers.

Authors:  Olga M Hernandez; Danuta Szczesna-Cordary; Björn C Knollmann; Todd Miller; Michael Bell; Jiaju Zhao; Syevda G Sirenko; Zoraida Diaz; Georgianna Guzman; Yuanyuan Xu; Ying Wang; W Glenn L Kerrick; James D Potter
Journal:  J Biol Chem       Date:  2005-08-22       Impact factor: 5.157

2.  Time and calcium dependence of activation and inactivation of calcium-induced release of calcium from the sarcoplasmic reticulum of a skinned canine cardiac Purkinje cell.

Authors:  A Fabiato
Journal:  J Gen Physiol       Date:  1985-02       Impact factor: 4.086

3.  A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia.

Authors:  Belinda Gray; Richard D Bagnall; Lien Lam; Jodie Ingles; Christian Turner; Eric Haan; Andrew Davis; Pei-Chi Yang; Colleen E Clancy; Raymond W Sy; Christopher Semsarian
Journal:  Heart Rhythm       Date:  2016-05-05       Impact factor: 6.343

4.  Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor.

Authors:  Hitoshi Uchinoumi; Masafumi Yano; Takeshi Suetomi; Makoto Ono; Xiaojuan Xu; Hiroki Tateishi; Tetsuro Oda; Shinichi Okuda; Masahiro Doi; Shigeki Kobayashi; Takeshi Yamamoto; Yasuhiro Ikeda; Tomoko Ohkusa; Noriaki Ikemoto; Masunori Matsuzaki
Journal:  Circ Res       Date:  2010-03-11       Impact factor: 17.367

5.  Calsequestrin isoforms localize to different ER subcompartments: evidence for polymer and heteropolymer-dependent localization.

Authors:  Michelle L Milstein; Timothy D Houle; Steven E Cala
Journal:  Exp Cell Res       Date:  2008-11-25       Impact factor: 3.905

6.  A case of catecholaminergic polymorphic ventricular tachycardia caused by two calsequestrin 2 mutations.

Authors:  Sam de la Fuente; Irene M Van Langen; Alex V Postma; Henni Bikker; Albert Meijer
Journal:  Pacing Clin Electrophysiol       Date:  2008-07       Impact factor: 1.976

7.  Hierarchical statistical techniques are necessary to draw reliable conclusions from analysis of isolated cardiomyocyte studies.

Authors:  Markus B Sikkel; Darrel P Francis; James Howard; Fabiana Gordon; Christina Rowlands; Nicholas S Peters; Alexander R Lyon; Sian E Harding; Kenneth T MacLeod
Journal:  Cardiovasc Res       Date:  2017-12-01       Impact factor: 10.787

8.  The structure of a calsequestrin filament reveals mechanisms of familial arrhythmia.

Authors:  Erron W Titus; Frederick H Deiter; Chenxu Shi; Julianne Wojciak; Melvin Scheinman; Natalia Jura; Rahul C Deo
Journal:  Nat Struct Mol Biol       Date:  2020-10-12       Impact factor: 15.369

9.  Cardiac-specific deletion of voltage dependent anion channel 2 leads to dilated cardiomyopathy by altering calcium homeostasis.

Authors:  Thirupura S Shankar; Dinesh K A Ramadurai; Kira Steinhorst; Salah Sommakia; Rachit Badolia; Aspasia Thodou Krokidi; Dallen Calder; Sutip Navankasattusas; Paulina Sander; Oh Sung Kwon; Aishwarya Aravamudhan; Jing Ling; Andreas Dendorfer; Changmin Xie; Ohyun Kwon; Emily H Y Cheng; Kevin J Whitehead; Thomas Gudermann; Russel S Richardson; Frank B Sachse; Johann Schredelseker; Kenneth W Spitzer; Dipayan Chaudhuri; Stavros G Drakos
Journal:  Nat Commun       Date:  2021-07-28       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.